BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

...data showing zanidatamab led to a confirmed objective response rate (ORR) of 47% in 15 Herceptin trastuzumab-naïve...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...in the towel. Prior failures in the class included Phase III disappointments for torcetrapib from Pfizer...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...after neoadjuvant treatment with J&J’s Erleada apalutamide, Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) and Pfizer...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...isolated from across the globe and assembled by pharmas including Merck & Co. Inc. (NYSE:MRK), Pfizer...
BioCentury | Jan 13, 2021
Product Development

mRNA vaccines still lead the COVID-19 pack: Data Byte

...of the vaccines that have had efficacy readouts since the mRNA vaccines from Moderna Inc. (NASDAQ:MRNA) and partners Pfizer...
...JNJ-78436735 from Johnson & Johnson (NYSE:JNJ), for which data are expected this month. Selina Koch Moderna Inc. Sinovac Biotech Ltd. Pfizer...
BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

...America that every dose of Moderna COVID-19 Vaccine from Moderna Inc. (NASDAQ:MRNA) and Comirnaty from Pfizer...
...Epidermal growth factor receptorHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 BC Staff Regeneron Pharmaceuticals Moderna Inc. BioNTech Pfizer Black...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

...election cycle, 14 PhRMA members contributed more than the trade association to political candidates, with Pfizer...
...Roger Marshall (Kan.), as well to a number of House members who disputed the election results.Pfizer...
...period that we’re in," Bradley said. Steve Usdin Biotechnology Innovation Organization Pharmaceutical Research and Manufacturers of America (PhRMA) Amgen Inc. Pfizer...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...raised $28 million in an A round in 2018, bringing its total investment to $72 million.Pfizer...
...Inc. (NYSE:PFE) invested $25 million in microbiome company Vedanta Biosciences Inc. as part of the Pfizer...
...in inflammatory bowel disease (IBD), which is expected to start in 2021. Michael Vincent, CSO of Pfizer’s...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

...week, Albert Bourla, chairman and CEO of Pfizer...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...CEO Elvire Gouze founded, was acquired by Pfizer...
...the firm a regulatory specialist. Desfontaine joined Wyeth (now Pfizer...
Items per page:
1 - 10 of 11167